ID   MK15_RAT                Reviewed;         547 AA.
AC   Q9Z2A6;
DT   18-APR-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2002, sequence version 2.
DT   02-OCT-2024, entry version 168.
DE   RecName: Full=Mitogen-activated protein kinase 15 {ECO:0000305};
DE            Short=MAP kinase 15;
DE            Short=MAPK 15;
DE            EC=2.7.11.24;
DE   AltName: Full=Extracellular signal-regulated kinase 7;
DE            Short=ERK-7;
DE   AltName: Full=Extracellular signal-regulated kinase 8;
DE            Short=ERK-8;
GN   Name=Mapk15;
GN   Synonyms=Erk7 {ECO:0000303|PubMed:9891064},
GN   Erk8 {ECO:0000303|PubMed:11875070};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, DOMAIN, TISSUE SPECIFICITY,
RP   SUBCELLULAR LOCATION, CHARACTERIZATION, PHOSPHORYLATION AT THR-176 AND
RP   TYR-178, MUTAGENESIS OF LYS-43; THR-176; TYR-178 AND 176-THR--TYR-178, AND
RP   ACTIVITY REGULATION.
RC   STRAIN=Sprague-Dawley; TISSUE=Testis;
RX   PubMed=9891064; DOI=10.1128/mcb.19.2.1301;
RA   Abe M.K., Kuo W.-L., Hershenson M.B., Rosner M.R.;
RT   "Extracellular signal-regulated kinase 7 (ERK7), a novel ERK with a C-
RT   terminal domain that regulates its activity, its cellular localization, and
RT   cell growth.";
RL   Mol. Cell. Biol. 19:1301-1312(1999).
RN   [2]
RP   PROTEIN SEQUENCE OF 154-161, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   STRAIN=Sprague-Dawley; TISSUE=Brain;
RA   Lubec G., Kang S.U.;
RL   Submitted (JUL-2007) to UniProtKB.
RN   [3]
RP   INTERACTION WITH CLIC3, AND SUBCELLULAR LOCATION.
RX   PubMed=9880541; DOI=10.1074/jbc.274.3.1621;
RA   Qian Z., Okuhara D., Abe M.K., Rosner M.R.;
RT   "Molecular cloning and characterization of a mitogen-activated protein
RT   kinase-associated intracellular chloride channel.";
RL   J. Biol. Chem. 274:1621-1627(1999).
RN   [4]
RP   DOMAIN, AND CHARACTERIZATION.
RX   PubMed=11287416; DOI=10.1074/jbc.m100026200;
RA   Abe M.K., Kahle K.T., Saelzler M.P., Orth K., Dixon J.E., Rosner M.R.;
RT   "ERK7 is an autoactivated member of the MAPK family.";
RL   J. Biol. Chem. 276:21272-21279(2001).
RN   [5]
RP   FUNCTION.
RX   PubMed=11875070; DOI=10.1074/jbc.m112483200;
RA   Abe M.K., Saelzler M.P., Espinosa R. III, Kahle K.T., Hershenson M.B.,
RA   Le Beau M.M., Rosner M.R.;
RT   "ERK8, a new member of the mitogen-activated protein kinase family.";
RL   J. Biol. Chem. 277:16733-16743(2002).
RN   [6]
RP   UBIQUITINATION, AND TISSUE SPECIFICITY.
RX   PubMed=15033983; DOI=10.1074/jbc.m313696200;
RA   Kuo W.-L., Duke C.J., Abe M.K., Kaplan E.L., Gomes S., Rosner M.R.;
RT   "ERK7 expression and kinase activity is regulated by the ubiquitin-
RT   proteosome pathway.";
RL   J. Biol. Chem. 279:23073-23081(2004).
CC   -!- FUNCTION: Atypical MAPK protein that regulates several process such as
CC       autophagy, ciliogenesis, protein trafficking/secretion and genome
CC       integrity, in a kinase activity-dependent manner. Controls both, basal
CC       and starvation-induced autophagy throught its interaction with GABARAP,
CC       MAP1LC3B and GABARAPL1 leading to autophagosome formation, SQSTM1
CC       degradation and reduced MAP1LC3B inhibitory phosphorylation. Regulates
CC       primary cilium formation and the localization of ciliary proteins
CC       involved in cilium structure, transport, and signaling. Prevents the
CC       relocation of the sugar-adding enzymes from the Golgi to the
CC       endoplasmic reticulum, thereby restricting the production of sugar-
CC       coated proteins. Upon amino-acid starvation, mediates transitional
CC       endoplasmic reticulum site disassembly and inhibition of secretion.
CC       Binds to chromatin leading to MAPK15 activation and interaction with
CC       PCNA, that which protects genomic integrity by inhibiting MDM2-mediated
CC       degradation of PCNA. Regulates DA transporter (DAT) activity and
CC       protein expression via activation of RhoA. In response to H(2)O(2)
CC       treatment phosphorylates ELAVL1, thus preventing it from binding to the
CC       PDCD4 3'UTR and rendering the PDCD4 mRNA accessible to miR-21 and
CC       leading to its degradation and loss of protein expression (By
CC       similarity). Also functions in a kinase activity-independent manner as
CC       a negative regulator of growth (PubMed:9891064). Phosphorylates in
CC       vitro FOS and MBP (PubMed:11875070). During oocyte maturation, plays a
CC       key role in the microtubule organization and mei- otic cell cycle
CC       progression in oocytes, fertilized eggs, and early embryos (By
CC       similarity). Interacts with ESRRA promoting its re-localization from
CC       the nucleus to the cytoplasm and then prevents its transcriptional
CC       activity (By similarity). {ECO:0000250|UniProtKB:Q80Y86,
CC       ECO:0000250|UniProtKB:Q8TD08, ECO:0000269|PubMed:11875070,
CC       ECO:0000269|PubMed:9891064}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.24;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.24;
CC   -!- ACTIVITY REGULATION: Activated by threonine and tyrosine
CC       phosphorylation. Inhibited by dual specificity phosphatases, such as
CC       DUSP1 (By similarity). Phosphorylation and activation in response to
CC       DNA damaging agents, serum stimulation. Constitutively activated when
CC       phosphorylated on Tyr-178. Activity depends on the relative rates of
CC       MAPK15 autophosphorylation and dephosphorylation by PTPN1 (By
CC       similarity). {ECO:0000250|UniProtKB:Q8TD08,
CC       ECO:0000269|PubMed:9891064}.
CC   -!- SUBUNIT: Interacts with CSK/c-Src, ABL1, RET and TGFB1I1. Interacts
CC       with GABARAP, MAP1LC3B and GABARAPL1; controls, in a kinase-dependent
CC       fashion, both basal and starvation-induced autophagy. Interacts with
CC       ESRRA; promotes re-localization of ESRRA to the cytoplasm through a
CC       XPO1-dependent mechanism then inhibits ESRRA transcriptional activity.
CC       Interacts with PCNA; the interaction is chromatin binding- and kinase
CC       activity-dependent and prevents MDM2-mediated PCNA destruction by
CC       inhibiting the association of PCNA with MDM2 (By similarity). Interacts
CC       with DVL2 (By similarity). Interacts with CLIC3; MAPK15 does not
CC       phosphorylates CLIC3 (PubMed:9880541). {ECO:0000250|UniProtKB:Q80Y86,
CC       ECO:0000250|UniProtKB:Q8TD08, ECO:0000269|PubMed:9880541}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, cilium basal body
CC       {ECO:0000250|UniProtKB:Q8TD08}. Cell junction, tight junction
CC       {ECO:0000250|UniProtKB:Q8TD08}. Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome, centriole
CC       {ECO:0000250|UniProtKB:Q8TD08}. Cytoplasmic vesicle, autophagosome
CC       {ECO:0000250|UniProtKB:Q8TD08}. Golgi apparatus
CC       {ECO:0000250|UniProtKB:Q8TD08}. Nucleus {ECO:0000269|PubMed:9880541,
CC       ECO:0000269|PubMed:9891064}. Cytoplasm {ECO:0000250|UniProtKB:Q8TD08}.
CC       Cytoplasm, cytoskeleton, spindle {ECO:0000250|UniProtKB:Q80Y86}.
CC       Note=Co-localizes to the cytoplasm only in presence of ESRRA.
CC       Translocates to the nucleus upon activation (By similarity). At
CC       prometaphase I, metaphase I (MI), anaphase I, telophase I, and
CC       metaphase II (MII) stages, is stably detected at the spindle (By
CC       similarity). {ECO:0000250|UniProtKB:Q80Y86,
CC       ECO:0000250|UniProtKB:Q8TD08}.
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed at a weak level. Highest
CC       expression is found in testis and to a lower extent in lung.
CC       {ECO:0000269|PubMed:15033983, ECO:0000269|PubMed:9891064}.
CC   -!- DOMAIN: C-terminal domain, rather than the kinase activity, is required
CC       for the full function of the enzyme. This region may be a protein
CC       interaction domain that regulates kinase localization, activation and
CC       transcriptional activity. When C-terminally truncated, the enzyme shows
CC       a reduction in the Thr-Glu-Tyr (TEY) phosphorylation level, in the in
CC       vitro kinase activity, in its nuclear localization and in its
CC       inhibitory effect on cell growth.
CC   -!- DOMAIN: The N-terminal region (1-20) is the minimal region necessary
CC       for ubiquitination and further proteasomal degradation.
CC   -!- DOMAIN: The TXY motif contains the threonine and tyrosine residues
CC       whose phosphorylation activates the MAP kinases.
CC   -!- PTM: Autophosphorylated on Thr-176 and Tyr-178; activates the enzyme.
CC       {ECO:0000269|PubMed:9891064}.
CC   -!- PTM: Dephosphorylated by PTPN1. {ECO:0000250|UniProtKB:Q8TD08}.
CC   -!- PTM: Ubiquitinated. Ubiquitination may allow its tight kinase activity
CC       regulation and rapid turnover. May be ubiquitinated by a SCF E3 ligase.
CC       {ECO:0000269|PubMed:15033983}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr
CC       protein kinase family. MAP kinase subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF078798; AAD12719.2; -; mRNA.
DR   RefSeq; NP_775453.1; NM_173331.2.
DR   RefSeq; XP_006241841.1; XM_006241779.3.
DR   AlphaFoldDB; Q9Z2A6; -.
DR   SMR; Q9Z2A6; -.
DR   IntAct; Q9Z2A6; 1.
DR   MINT; Q9Z2A6; -.
DR   STRING; 10116.ENSRNOP00000075332; -.
DR   iPTMnet; Q9Z2A6; -.
DR   PhosphoSitePlus; Q9Z2A6; -.
DR   jPOST; Q9Z2A6; -.
DR   PaxDb; 10116-ENSRNOP00000012460; -.
DR   Ensembl; ENSRNOT00000012461.5; ENSRNOP00000012460.3; ENSRNOG00000009336.6.
DR   Ensembl; ENSRNOT00060036494; ENSRNOP00060030033; ENSRNOG00060021050.
DR   Ensembl; ENSRNOT00065015061; ENSRNOP00065011266; ENSRNOG00065009415.
DR   GeneID; 286997; -.
DR   KEGG; rno:286997; -.
DR   AGR; RGD:628675; -.
DR   CTD; 225689; -.
DR   RGD; 628675; Mapk15.
DR   eggNOG; KOG0660; Eukaryota.
DR   GeneTree; ENSGT00940000159758; -.
DR   HOGENOM; CLU_000288_181_14_1; -.
DR   InParanoid; Q9Z2A6; -.
DR   OrthoDB; 117891at2759; -.
DR   PhylomeDB; Q9Z2A6; -.
DR   TreeFam; TF105101; -.
DR   PRO; PR:Q9Z2A6; -.
DR   Proteomes; UP000002494; Chromosome 7.
DR   Bgee; ENSRNOG00000009336; Expressed in testis and 12 other cell types or tissues.
DR   ExpressionAtlas; Q9Z2A6; baseline and differential.
DR   GO; GO:0005776; C:autophagosome; ISS:UniProtKB.
DR   GO; GO:0005923; C:bicellular tight junction; IEA:UniProtKB-SubCell.
DR   GO; GO:0005911; C:cell-cell junction; ISS:UniProtKB.
DR   GO; GO:0005814; C:centriole; ISS:UniProtKB.
DR   GO; GO:0036064; C:ciliary basal body; ISS:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IEA:UniProtKB-KW.
DR   GO; GO:0005794; C:Golgi apparatus; ISS:UniProtKB.
DR   GO; GO:0072687; C:meiotic spindle; ISO:RGD.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003682; F:chromatin binding; ISS:UniProtKB.
DR   GO; GO:0016301; F:kinase activity; ISS:UniProtKB.
DR   GO; GO:0004707; F:MAP kinase activity; ISS:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; ISS:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0006974; P:DNA damage response; ISO:RGD.
DR   GO; GO:0090494; P:dopamine uptake; ISS:UniProtKB.
DR   GO; GO:0007029; P:endoplasmic reticulum organization; ISS:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0030336; P:negative regulation of cell migration; ISS:UniProtKB.
DR   GO; GO:0008156; P:negative regulation of DNA replication; IMP:RGD.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IMP:RGD.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; ISS:UniProtKB.
DR   GO; GO:1905188; P:positive regulation of metaphase/anaphase transition of meiosis I; ISO:RGD.
DR   GO; GO:0045732; P:positive regulation of protein catabolic process; IMP:RGD.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:RGD.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; IMP:RGD.
DR   GO; GO:1905832; P:positive regulation of spindle assembly; ISO:RGD.
DR   GO; GO:1904355; P:positive regulation of telomere capping; ISO:RGD.
DR   GO; GO:0032212; P:positive regulation of telomere maintenance via telomerase; ISO:RGD.
DR   GO; GO:0046777; P:protein autophosphorylation; ISS:UniProtKB.
DR   GO; GO:1904491; P:protein localization to ciliary transition zone; ISO:RGD.
DR   GO; GO:0010506; P:regulation of autophagy; ISS:UniProtKB.
DR   GO; GO:1902017; P:regulation of cilium assembly; ISS:UniProtKB.
DR   GO; GO:0003400; P:regulation of COPII vesicle coating; ISS:UniProtKB.
DR   GO; GO:0032355; P:response to estradiol; IMP:RGD.
DR   CDD; cd07852; STKc_MAPK15-like; 1.
DR   Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR050117; MAP_kinase.
DR   InterPro; IPR003527; MAP_kinase_CS.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   PANTHER; PTHR24055; MITOGEN-ACTIVATED PROTEIN KINASE; 1.
DR   PANTHER; PTHR24055:SF79; MITOGEN-ACTIVATED PROTEIN KINASE 15; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SUPFAM; SSF56112; Protein kinase-like (PK-like); 1.
DR   PROSITE; PS01351; MAPK; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   ATP-binding; Cell junction; Cell projection; Cytoplasm;
KW   Cytoplasmic vesicle; Cytoskeleton; Direct protein sequencing;
KW   Golgi apparatus; Kinase; Methylation; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Tight junction; Transferase;
KW   Ubl conjugation.
FT   CHAIN           1..547
FT                   /note="Mitogen-activated protein kinase 15"
FT                   /id="PRO_0000232639"
FT   DOMAIN          14..305
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REPEAT          378..382
FT                   /note="PXXXP motif"
FT                   /evidence="ECO:0000250|UniProtKB:Q8TD08"
FT   REPEAT          385..389
FT                   /note="PXXXP motif"
FT                   /evidence="ECO:0000250|UniProtKB:Q8TD08"
FT   REPEAT          393..397
FT                   /note="PXXXP motif; regulates binding with chromatin and
FT                   interaction with PCNA"
FT                   /evidence="ECO:0000250|UniProtKB:Q8TD08"
FT   REPEAT          401..405
FT                   /note="PXXXP motif; regulates binding with chromatin and
FT                   interaction with PCNA"
FT                   /evidence="ECO:0000250|UniProtKB:Q8TD08"
FT   REGION          1..20
FT                   /note="Ubiquitin-conjugating"
FT   REGION          266..286
FT                   /note="Necessary to interact with ESRRA, to regulate its
FT                   subcellular localization and to inhibit its transcriptional
FT                   activity"
FT                   /evidence="ECO:0000250|UniProtKB:Q8TD08"
FT   REGION          301..380
FT                   /note="Requires for interaction with GABARAP, MAP1LC3B AND
FT                   GABARAPL1"
FT                   /evidence="ECO:0000250|UniProtKB:Q8TD08"
FT   REGION          370..503
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           176..178
FT                   /note="TXY"
FT   COMPBIAS        397..413
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        423..437
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        451..465
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        138
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         20..28
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         43
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         176
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:9891064"
FT   MOD_RES         178
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:9891064"
FT   MOD_RES         449
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8TD08"
FT   MUTAGEN         43
FT                   /note="K->R: Loss of autophosphorylation and activity."
FT                   /evidence="ECO:0000269|PubMed:9891064"
FT   MUTAGEN         176
FT                   /note="T->A: Loss of autophosphorylation and activity. Loss
FT                   of autophosphorylation and activity; when associated with
FT                   F-178."
FT                   /evidence="ECO:0000269|PubMed:9891064"
FT   MUTAGEN         178
FT                   /note="Y->F: Loss of autophosphorylation and activity. Loss
FT                   of autophosphorylation and activity; when associated with
FT                   A-176."
FT                   /evidence="ECO:0000269|PubMed:9891064"
SQ   SEQUENCE   547 AA;  60724 MW;  D8B7D9955B06862F CRC64;
     MCAAEVDRHV SQRYLIKRRL GKGAYGIVWK AMDRRTGEVV AIKKIFDAFR DQTDAQRTFR
     EIMLLREFGG HPNIIRLLDV IPAKNDRDIY LVFESMDTDL NAVIQKGRLL EDIHKRCIFY
     QLLRATKFIH SGRVIHRDQK PANVLLDAAC RVKLCDFGLA RSLSDFPEGP GGQALTEYVA
     TRWYRAPEVL LSSRWYTPGV DMWSLGCILG EMLRGQPLFP GTSTFHQLEL ILETIPLPSM
     EELQGLGSDY SALILQNLGS RPRQTLDALL PPDTPPEALD LLKRLLAFAP DKRLSAEQAL
     QHPYVQRFHC PDREWTRGSD VRLPVHEGDQ LSAPEYRNRL YQMILERRRN SRSPREEDLG
     VVASRAELRA SQRQSLKPGV LPQVLAETPA RKRGPKPQNG HGHDPEHVEV RRQSSDPLYQ
     LPPPGSGERP PGATGEPPSA PSGVKTHVRA VAPSLTSQAA AQAANQPLIR SDPARGGGPR
     AVGARRVPSR LPREAPEPRP GRRMFGISVS QGAQGAARAA LGGYSQAYGT VCRSALGRLP
     LLPGPRA
//
